This May, Steadli joined Life Sciences Central at MaRS Discovery District in Toronto, one of the largest health and technology innovation hubs in North America. For a small team building a chronic care company, that membership gives us advisory relationships with people who have built and scaled health ventures before us, warm introductions to investors who already understand this space, and a way into the broader MaRS health venture network instead of finding our way in cold.
Why chronic care, and why now
Steadli started with GLP-1 medications as our entry point, because that's where there is a ton of momentum right now. More people every year are starting Ozempic, Wegovy, Mounjaro, or Zepbound and discovering that the medication alone doesn't rebuild the habits around food, movement, and daily routine that make the results stick around, but the company we're building isn't tied to one medication. What we are working on is the layer of behavior change that chronic care has always struggled to deliver: the daily, unglamorous work of building habits that hold up over years for people managing diabetes, obesity, hypertension, and the conditions that tend to travel together.
We're making a bet on how people actually change, and that goes more smoothly when you're near people who have been in the space already.
What this means for us
Joining Life Sciences Central puts Steadli inside a community of advisors, investors, and health ventures who take chronic care seriously as its own category, at a stage when we can put the introductions and the outside perspective to real use.
We'll keep building. If you work in chronic care, health venture investing, or adjacent digital health and want to compare notes, reach out. I read every email myself.
- Michael.